The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembran...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Galimberti, Sara, Bucelli, Cristina, Arrigoni, Elena, Baratè, Claudia, Grassi, Susanna, Ricci, Federica, Guerrini, Francesca, Ciabatti, Elena, Fava, Carmen, D’Avolio, Antonio, Fontanelli, Giulia, Cambrin, Giovanna Rege, Isidori, Alessandro, Loscocco, Federica, Caocci, Giovanni, Greco, Marianna, Bocchia, Monica, Aprile, Lara, Gozzini, Antonella, Scappini, Barbara, Cattaneo, Daniele, Scortechini, Anna Rita, La Nasa, Giorgio, Bosi, Alberto, Leoni, Pietro, Danesi, Romano, Saglio, Giuseppe, Visani, Giuseppe, Cortelezzi, Agostino, Petrini, Mario, Iurlo, Alessandra, Di Paolo, Antonello
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675690/
https://ncbi.nlm.nih.gov/pubmed/29152138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21406
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak